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Background: Peptidylarginine deiminase IV (PADI4) is widely distributed in several tissues and the expression is
correlated with many pathological processes. Chemotherapy remains a major treatment alternatively to surgery for
a large number of patients at the advanced stage of hepatocellular carcinoma (HCC). However, the role of PADI4 in
the chemoresistance of HCC has not been identified.
Methods: MTT and PI/Annexin V assay were employed to examine the proliferation and apoptosis of HCC cell lines.
The expression of MDR1 is detected by Realtime PCR. GFP tagged LC3 expression vector and electron microscopy
are utilized to demonstrate the occurrence of autophagy.
Results: We observed that the elevated PADI4 expression is associated with chemoresistance in HCC patients with
TACE after surgery. In addition, we found that overexpression of PADI4 in HCC cell lines lead to the resistance to
chemotherapeutic agents in vitro and in vivo. Interestingly, the HCC cells that overexpressed PADI4 were observed
to undergo autophagy which was known as a protective mechanism for cells to resist the cell tosicity from
chemotherapy. Autophagy inhibitor could effectively restore the sensitivity of HCC cells to chemotherapy in vitro
and in vivo.
Conclusions: These results indicate that PADI4 may induce chemoresistance in HCC cells by leading autophagy.
Keywords: PADI4, Autophagy, Hepatocellular Carcinoma, ChemoresistanceBackground
Peptidylarginine deiminases (PADs) enzymes distributed
widely in mammals and their function is closely associ-
ated with the development and differentiation of the
cells [1]. PADs can convert protein Arg residues to cit-
rulline in a calcium and sulfhydryl group dependent
manner, which play an important role in several physio-
logical and pathological processes such as gene expres-
sion regulation, epithelial terminal differentiation and
apoptosis [2].* Correspondence: lixinwei@smmu.edu.cn; flieying@126.com
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unless otherwise stated.There are five types of PAD enzymes in human and
mouse, including PADI1-4 and PAD6 [1,3]. PADI4 has
been reported to express in several type of cells, includ-
ing embryonic stem cells, leukocytes and breast cancer
cells. Furthermore, PADI4 is also involved in the etiology
of cancers and rheumatoid arthritis in human [4-6]. The
results from immunohistochemistry demonstrates that
PADI4 is expressed not only in various adenocarcinoma,
but also in some non-adenocarcinoma tumors such as
bone osteosarcoma, liver cholangiocellular carcinoma,
liver hepatocellular carcinoma and lung squamous car-
cinoma [7]. These results indicates that PADI4 may play
an important role in tumorigenesis [8].
Hepatocellular carcinoma (HCC) is a common malig-
nant tumor in China, which surgical resection is consid-
ered as the most effective treatment. Chemotherapy
remains to be a major treatment alternatively to surgery. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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HCC. However, chemoresistance in HCC is still a prom-
inent obstacle for effective treatment of HCC with
chemotherapy. Therefore, the underlying molecular
mechanisms of HCC chemoresistance and how to over-
come them is still a critical issue for us to identify. The
role of PADI4 for chemoresistance of HCC cells has not
been identified. In this study, we will investigate the role
of PADI4 for chemoresistance in HCC and the potential
mechanism will could be explored.
Methods
Patients and tissue specimens
Specimens of HCC tissues were obtained from 120 HCC
patients who underwent hepatic resection at Eastern
Hepatobiliary Surgery Hospital of Second Military Medical
University from February 1998 to December 2010. These
patients included 90 males and 30 females with a median
age of 51 years (range: 31–73). All tumors were histologi-
cally diagnosed as HCC according to the Edmondson-
Steiner classification system. In all cases, H&E-stained
slides were re-examined independently by three experi-
enced pathologists without any knowledge of clinical data.
Written informed consent was obtained from each patient,
and the protocol of the study was approved by the ethics
committee of Second Military Medical University.
Cell lines and reagents
HCC cell lines including SMMC-7721 cells and Hep-G2
cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) (GIBCO, Invitrogen) with 10% fetal bovine serum
(FBS) at 37°C in a humidified atmosphere containing
5% CO2. The chemotherapeutic agents: cisplatin and
5-fluorouracil (5-FU) were purchased from Qilu Pharma-
ceutical Co., Ltd. (JiNan, Shandong, China). 3-methyladenine
(3-MA) (Sigma-Aldrich, Cat.M9281) was used at 10 mM.
Adenoviral vectors
The adenoviral vector expressing PADI4 under a cyto-
megalovirus promoter promoter—AdPADI4 was used to
overexpress PADI4 in HCC cell lines. Ad-Vector (con-
trol adenovirus) infected group was used as controls in
the subsequent experiments.
HCC cell treatment
To investigate the effect of PADI4 on the chemotherapy
sensitivity of HCC cells, the cells were infected with
AdPADI4 and then collected for the determinations of cell
viability, apoptosis and the autophagy associated genes
expression.
Quantitative real-time PCR analysis for mRNA expression
RNA was isolated from tumor tissues, and blood samples.
In brief, total RNA was extracted with TRIzol reagent,according to the protocol provided by the manufacturer.
The quantity and quality of the RNA samples were mea-
sured carefully by spectrophotometer and electrophoresis.
The first-strand cDNA was synthesised from 2 μg of total
RNA. Primer sequences of PADI4 for reverse transcription-
PCR (RT-PCR) reaction were forward (5′-CACAGCTCTG
GTTGGCTTCA-3′) and reverse (5′-CTGCACGTCCTTC
AGCATCA-3′) [9]. Primer sequences of MDR1 for reve
rse transcription-PCR (RT-PCR) reaction were forward (5′-
CTGGTTTGATGTGCACGATGTTGG-3′) and reverse
(5′- TGCCAAG-ACCTCTTCAGCTACTG-3′) [10]. Quan-
titative real-time PCR (qPCR) were carried out by using the
Mx3000P QPCR System (Stratagene, USA). As an in-
ternal control for qPCR, β-actin mRNA expression was
amplified from the same cDNA samples. All results were
normalized to β-actin amplification. CT values for tripli-
cate reactions were averaged and relative expression was
determined with the comparative CT method, using aver-
age CT values.
MTT colorimetric assay
In order to examine the effect of PADI4 on the chemo-
sensitivity of HCC cells, HCC cells were seeded in 96-
well plates at a density of 1 × 104 cells/well and cultured
in the medium containing chemotherapeutic agents with
Ad-PADI4. The cell viability in each well was examined
by a MTT (5 mg/ml, Sigma, Cat.M2003) colorimetric
assay. The optical density (OD) value at 490 nm of each
sample was measured using a plate reader. The data was
expressed as mean ± SD.
Cell apoptosis assay
HCC cells (2 × 105 cells/well) were cultured in 6-well
plates to 70–80% confluence. The cells were then treated
with chemotherapeutic agents for 8 h in the absence and
presence of MSC conditioned medium. In a subset of ex-
periments, 3-MA (5 mM) was used to block autophagy.
PI/Annexin V-PE assay was used to measure apoptotic
cells by flow cytometry according to the manufacturer’s
instruction (Keygen Biotech. Co., Ltd, Nanjing, Jiangsu,
China, Cat.KGA108). Briefly, cells collected by trypsiniza-
tion were washed trice with ice cold phosphate-buffered
saline (PBS). Cells were then incubated in 300 μL of 1×
binding buffer containing 5 μL Annexin V and 5 μL PI for
30 min at room temperature in the dark. Apoptosis of
cells was measured on a BD FACSAria flow cytometer
(Becton Dickinson, Lincoln Park, NJ). At least 30,000
gated events were acquired from each sample. Results are
expressed as the percentage of apoptotic cells (PI and
Annexin V positive) in the gated cell population.
Transient transfection and identification of autophagy
GFP tagged LC3 expression vector has recently been uti-
lized to demonstrate the occurrence of autophagy. SMMC-
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96-well plates overnight. GFP-LC3 expressing plasmids
were transiently transfected into cells using the Fugene
HD transfection reagent (Roche, Cat.04709705001) ac-
cording to the manufacturer’s instruction. After being cul-
tured for 24 h to ensure expression of GFP-LC3, the cells
were treated with Ad-PADI4 for 8 h. At the end of each
experiment, autophagy was detected by counting the per-
centage of cells with GFP-LC3-positive dots under fluores-
cence microscope (Olympus IX71). A minimum of 200
cells were counted in each sample. The experiment was
conducted in triplicate.
Electron microscopy
HCC cells were sequentially fixed with 2.5% glutaralde-
hyde acid in 0.1 M PBS buffer (pH 7.4) for 2 h, incu-
bated in 1% osmium tetroxide in 0.1 M PBS buffer
(pH 7.4) for 2–3 h, dehydrated in solutions of ethanol
and acetone, embedded in Araldite, and finally solidi-
fied. Sections (50–60 nm) were cut on a LKB-I ultrami-
crotome and picked up on copper grids. After being
post-stained with uranyl acetate and lead citrate, sam-
ple sections were observed with a Philips CM-120
TEM (Philips).
Western blot analysis
HCC cell lines were washed in PBS and lysed in RIPA buf-
fer with 1 mM PMSF on ice. Cell lysates were centrifuged
(12,000 rpm, 10 min) at 4°C, the protein supernatant was
transferred into new tubes. The concentration of the pro-
tein samples was determined with BCA Protein Assay Kit
(Pierce, USA). A 20 μg sample of the total protein was
resolved using 12% SDS-PAGE and transferred onto
PVDF membranes. The membranes were blocked in Tris-
buffered saline containing Tween 20 (TBST) with 5% non-
fat milk at room temperature for 2 h. Primary antibodies
to detect PADI4(1:1000, Abcam, USA) and LC-3(1:1000,
Novus Biologicals, Inc) were incubated overnight with
the membranes at 4°C. Membranes were incubated with
horseradish peroxidase (HRP)-conjugated anti-rabbit sec-
ondary antibodies (1:8000, Dako, USA), and proteins
were detected by enhanced chemiluminescence (ECL)
(Beyotime, USA). GAPDH was used as the internal con-
trol to normalize the loading materials.
Animal model
All procedures involving animals were performed in ac-
cordance with the institutional animal welfare guidelines
of Second Military Medical University. Subcutaneous
implantation of HCC cells was performed in armpit
areas of nude mice. Mice were examined three times per
week. Tumor growth was evaluated by measuring the
length and width of the tumor mass. Animals were sacri-
ficed and tumors were removed at the end of theexperiment. Tumor masses were weighed and analyzed
by histology.
Short Hairpin RNA (shRNA) synthesis and transient
transfection
The shRNA sequences of PADI4, Atg7 and Beclin7 were
designed using Oligoengine software and verified by nu-
cleotide BLAST searches. The candidate sequences and
a scrambled sequence with no significant homology were
listed in Additional file 1: Table S1. The recombinant
virus was packaged using Lentivector Expression Sys-
tems (Shanghai GeneChem, Shanghai). Cells (1–3 × 106)
growing to 50%-60% confluence in 10 cm petri dishes
were transfected with shRNA sequences. Cells were ob-
served under a fluorescence microscope and harvested
48 h after transfection.
Statistical analysis
All data were generated without knowledge of the clin-
ical status of the samples analyzed by SPSS 18.0 software
(SPSS, Inc., Chicago, USA). Comparison was done with t
test (unpaired or paired). All P values presented were
two-sided, and a P value of less than 0.05 was considered
statistically significant.
Results
The elevated PADI4 expression is associated with
chemoresistance in HCC with Transcatheter arterial
chemoembolization (TACE)
We collected 5 ml vein blood samples before TACE and
after TACE in HCC patients with partial hepatectomy.
Chemoresistance were detected by MDR1 mRNA expres-
sion in blood samples by using Realtime-PCR. We found
that elevated expression of MDR1 after TACE was de-
tected in 72.5% of HCC patients (87/120), and lower ex-
pression of MDR1 was detected in 27.5% of HCC patients
(33/120) after TACE. Here, MDR1 (+) group means ele-
vated expression of MDR1, and MDR1 (−) group means
lower expression of MDR1 after TACE treatment for
HCC patients with partial hepatectomy. According to the
MDR1 results, all 120 HCC patients were divided into two
groups: the chemoresistance group–MDR1 (+) group, and
chemosensitivity group–MDR1 (−) group (Figure 1A).
However, there are no significant difference in clinicopath-
ologic variables between MDR1 (+) group and MDR1 (−)
group (Additional file 1: Table S2).
Time zero of recurrence-free survival of patients
treated with TACE is the date of TACE. All patients
underwent ultrasound, computed tomography scan or
magnetic resonance imaging of the abdomen once every
2 months after treatment. Kaplan–Meier analysis indi-
cated that the recurrence-free survival of MDR1 (+)
group was shorter than MDR1 (−) group (median:
6 months vs 9 months, respectively; P < 0 · 0001; HR:
Figure 1 The elevated PADI4 mRNA expression in MDR1(+) HCC patients with TACE. (A) The MDR1 mRNA expression were detected in
blood samples before and after TACE. - ΔΔCt, −(ΔCtbefore TACE – ΔCtafter TACE); MDR(+):- ΔΔCt > =0; MDR(−):- ΔΔCt < 0. (B) The progression-free
survival (PFS) after transcatheter arterial chemoembolization (TACE) in partial hepatectomy for hepatocellular carcinoma determined by Kaplan-Meier
analysis. (C) The PADI4 mRNA expression in HCC tumor tissues associated with chemoresistance. - ΔΔCt, −(ΔCtbefore TACE – ΔCtafter TACE); MDR(+):-
ΔΔCt > =0; MDR(−):- ΔΔCt < 0.
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found that PADI4 mRNA expression of tumor tissues was
higher in MDR1 (+) group (Mean -ΔCt ± SD = 0.59 ± 0.37)
than that in MDR1 (−) group (Mean -ΔCt ± SD = −1.69 ±
0.53). PADI4 expression of HCC tissues was significantly
difference between chemoresistance patients and chemo-
sensitivity patients (p = 0.0011; Figure 1C).
PADI4 enhanced chemoresistance of hepatocellular
carcinoma cells
In order to investigate the influence of PADI4 on the
chemoresistance in HCC cells, we observed the effect of
chemotherapeutic agent 5-Fu on morphological changes
of HCC cell line-SMMC7721 cells. The expression of
PADI4 in HCC cell lines was examined by western blot
and Ad-PADI4 was used to overexpress PADI4 in HCC
cell lines (Additional file 2: Figure S1). As shown in
Figure 2A, 5-Fu could effectively inhibit the growth of
SMMC7721 cells. Once PADI4 was overexpressed in
SMMC7721 cells, the inhibition effect induced by 5-Fu
was attenuated. We also observed the role of PADI4
on the proliferation of SMMC7721 and Hep-G2 cells
when they were exposed to chemotherapeutic agent.
The results demonstrated that overexpression of PADI4
significantly improved the chemoresistance capability
in hepatocarcinoma cell lines compared with control
groups (Figure 2B). In addition, we detected the effect
of PADI4 on the apoptosis of HCCs when they were
exposed to chemotherapeutic agent. The results showed
that PADI4 effectively decreased the apoptosis of
SMMC7721 cells induced by 5-Fu (Figure 2C). We
further examined the PADI4-induced chemoresistance
in HCC cells in the nude mouse model. As shown
in Figure 3A and B, compared with control groups,
PADI4 induced the resistance to chemotherapy in HCC
cells in vivo.Taken together, these data suggested that overexpres-
sion of PADI4 could effectively induce the chemoresis-
tance in HCC cells.
PADI4 induced autophagy in hepatocellular carcinoma cells
Autophagy has been reported to contribute to chemore-
sistance in HCC cells [11]. Therefore, we speculated that
PADI4 might lead to an incidence autophagy in HCC
cells. A vector that expresses encoding GFP-LC3 was
transmitted into SMMC7721 cells to detect the occur-
rence of autophagy. We determined the incidence of
autophagy in HCC cells when the punctuate GFP fluores-
cence was observed in a diffused GFP fluorescence. The
results showed that SMMC7721 with overexposed PADI4
exhibited a high percentage of punctuate GFP, which indi-
cated the occurrence of autophagy, while the fluorescence
in control groups remained to be diffused (Figure 4A and
B). Transmission electron microscopy was employed to
confirm the autophagy in SMMC7721 cells. As shown in
Figure 4C, SMMC7721 cells with overexpressed PADI4
demonstrated a marked autophagosomes accumulation,
which indicated the incidence of autophagy. Furthermore,
we examined the expression of LC3-I and LC3-II in HCC
cells by western blot. The level of LC3-I and LC3-II in-
creased in PADI4 overexpression groups and in hypoxia
treated group, which indicated that PADI4 could induce
autophagy in HCC cells (Figure 4D).
Inhibition of autophagy restored the sensitivity of HCC
cells to chemotherapy
In order to confirm the role of autophagy in enhancing
the chemoresistance of HCC cells, we observed the re-
covery of HCC cell sensitivity to chemotherapy leading
by autophagy inhibitors. The 3-MA is used as autophagy
inhibitor, which blocks the formation of autophagosomes
[12]. As shown in Figure 5, the results demonstrated
Figure 2 (See legend on next page.)
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Figure 2 PADI4 enhanced chemoresistance of hepatocellular carcinoma cells in vitro. (A) SMMC-7721 cells were treated with 5-Fu (120 μg/mL)
with overexpression of PADI4 or not. The morphology of the cells was observed by microscope. (B) PADI4 was overexpressed in SMMC-7721 or HepG2
cells and the cells (1 × 104/well) were cultured in a 96-well plate with an existence of 5-Fu (120 μg/mL) or cisplatin (8 μg/mL) for 24 hours. MTT was
employed to examine the viability of SMMC-7721 or Hep-G2 cells. (C) PADI4 was overexpressed in SMMC-7721 cells and the cells were cultured in a
6-well plate with an existence of 5-Fu (120 μg/mL) for 24 hours. Flow cytometry was used to measure apoptosis of the cells. (*Compared with the
group that untreated with chemotherapy drugs, P < 0.05; #Compared with the group that treated with chemotherapy drugs, P < 0.05)
Figure 3 PADI4 enhanced chemoresistance of hepatocellular
carcinoma cells in vivo. (A) PADI4 was overexpressed in SMMC-7721
cells and then the cells (5 × 106) to perform subcutaneous administration
in the nude mice armpit area. After implantation, recipients were
injected in tumor in situ with 5-Fu (30 mg/kg) every 3 days. After
27 days of implantation, the animals were sacrificed and tumors
were dissected. (B) The tumor weight and volume of each groups
were measured after been removed from the mice. (*P < 0.05)
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peutic sensitivity in HCC cells. Beside that, another
autophagy inhibitor-CQ demonstrated a same effect as
3-MA (Additional file 3: Figure S2). Furthermore, we
also employed shRNA-ATG7 or shRNA-Beclin1 to in-
hibit autophagy in HCC cells. As shown in Additional
file 4: Figure S3, shRNA-ATG7 and shRNA-Beclin1
could effectively inhibit the upregulation of ATG7 and
Beclin1 in HCC cells during cultured in hypoxia condi-
tion. The inhibition of ATG7 or Beclin1 respectively in
HCC cells effectively diminished the protection of au-
tophagy on chemoresistance.
Discussion
Hepatocellular carcinoma (HCC) is a common malig-
nant tumor in China, which surgical resection is consid-
ered as the most effective treatment. Chemotherapy
remains to be a major treatment alternatively to surgery
for a large number of patients at the advanced stage of
HCC. However, chemoresistance in HCC cells is still a
prominent obstacle for effective treatment of HCC with
chemotherapy.
Multiple drug resistance (MDR) phenotype, which
almost constantly expressed in HCC, is generally consid-
ered as a key cause of poor outcome in HCC chemother-
apy [13,14]. MDR is associated with overexpression of
the MDR1 gene and the expression of a transmembrane
glycoprotein of 150–180 kDa membrane phosphoglyco-
protein (P-gp). As a drug pump, it confers cancer cell re-
sistance to a broad range of structurally and functionally
diverse chemotherapeutic drugs [15,16]. It is well docu-
mented that MDR has frequently been associated with
elevated expression level of the MDR1/P-gp in hepato-
cellular carcinoma cell lines [17,18].
Protein citrullination had recently become an interest
area in some types of cancer. PADI4 was a transcriptional
coregulator that catalyzes the calcium-dependent conver-
sion of specific arginine residues in proteins to citrulline,
and had also been proposed to “reverse” epigenetic his-
tone modifications [19]. PADI4 expression was also sig-
nificantly detected in some non-adenocarcinoma tumors
such as liver cholangiocellular carcinoma and hepatocellu-
lar carcinoma, but the levels of PADI4 expression by im-
munohistochemistry or western blot analysis were very
different in various malignant tumor tissues and blood
Figure 4 PADI4 induced autophagy in hepatocellular carcinoma cells. (A) GFP-tagged LC3 plasmid was transfected into SMMC-7721 cells,
after 24 hours transfection, the cells were incubated with Ad-PADI4. Fluorescence microscope was used to observe the punctate GFP-LC3 in the
cytoplasm. (B) The number of punctate GFP-LC3 in each cell of SMMC-7721 and HepG2 was counted and at least 100 cells were included for each
group. (C) Electron micrographs was exployed to examine the autophagic vacuoles ultrastructure in the cytoplasm of SMMC-7721 and HepG2 cells
which PADI4 were overexpressed. Magnification, ×10,000. (D) Western blot was used to analysis the expression of LC3-I and LC3-II in SMMC7721 and
HepG2 cells. a-d: SMMC-7721 in different treatment conditions; e: HepG2 treated with Ad-PADI4. GAPDH expression was used as control.
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expression is associated with chemoresistance in HCC
patients with TACE after surgery. Therefore, we explore
the role of PADI4 in chemoresistance of HCC cells. We
found that overexpression of PADI4 in HCC cell lines
could lead to the resistance to chemotherapeutic agents
in vitro and in vivo.Autophagy is an evolutionarily conserved catabolic
process, which serve as a survival mechanism in a nutri-
ent deficient environment not only for prokaryotic but
also for eukaryotic cells [21,22]. The autophagy associ-
ated pathway consists three steps: formation of autopha-
gosome, lysosomal fusion with the autophagosome, and
lysosomal degradation to produce precursor molecules,
Figure 5 Inhibition of autophagy restored the sensitivity of HCC cells to chemotherapy. (A) SMMC-7721 and Hep-G2 cells (1 × 104/well)
that overexpressed PADI4 were cultured in a 96-well plate with an existence of 5-Fu (120 μg/mL) for 24 hours. The occurrence of autophagy was
inhibited by autophagy inhibitor-3-MA or sh-Atg7 and sh-Beclin1. MTT was used to detect the viability of the cells. (B) PADI4 was overexpressed
in SMMC-7721 cells. The occurrence of autophagy was inhibited by sh-Atg7. Then the cells (5 × 106) were performed subcutaneous administration
in the nude mice armpit area. After implantation, recipients were injected in tumor in situ with 5-Fu (30 mg/kg) every 3 days. After 27 days of
implantation, the animals were sacrificed and tumors were dissected. The tumor weight and volume of each groups were measured after been
removed from the mice. (*Compared with the group that untreated with chemotherapy drugs, P < 0.05; #Compared with the group that treated
with chemotherapy drugs, P < 0.05)
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ecules, to be reutilized for maintaining cellular homeo-
stasis and facilitating cell survival [23-26]. Autophagy
has been reported to be associated with several physio-
logical and pathological processes, including cell differ-
entiation, tumorigenesis and adaptation to changed
environmental conditions [27]. However, the role of
authphagy in tumorigenesis is still controversial. On one
hand, some studies reported that autophagy is essential
for the survival of cancer cells not only in cancer cells
but also in cancer stem cells [11,28]. On the other hand,prolonged autophagy will lead to non-apoptotic type II
programmed cell death [29,30].
In previous studies, we have demonstrated that au-
tophagy decreases the sensitivity of hepatoma cells to
chemotherapeutic agents by affecting their apoptotic po-
tential [11]. In addition, we have shown that autophagy
activated by hypoxia mediates the tolerance of hepato-
cellular carcinoma cells to nutrient deprivation, which is
dependent on the activity of Beclin 1 [19]. Wang, et al.
found that PADI4 regulates the mTORC1 signaling
pathway and PADI inhibitors are potential anticancer
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alone or in combination with HDAC inhibitors [31].
Interestingly, our study indicated that HCC cells with
overexpressed PADI4 were observed to undergo autoph-
agy, which is known as a protective mechanism for cells
to resist the cell toxicity from chemotherapy. Autophagy
inhibitor could effectively restore the sensitivity of HCC
cells to chemotherapy in vitro and in vivo. These results
indicate that PADI4 could induce chemoresistance in
HCC cells by leading autophagy.
Conclusions
Taken together, PADI4 could play an important role in
inducing chemoresistance in HCC cells, and the expres-
sion of PADI4 of tumor tissues in HCC patients could
be used as a prognostic indicator. However, this remains
a speculation and more studies are needed in the future
to elucidate the exact molecular mechanisms of PADI4
in HCC.
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